Falling incidence of Parkinson's disease in Germany.
Germany
Idiopathic Parkinson's disease
claims data
cohort study
cumulative incidence
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
28
06
2023
accepted:
22
07
2023
medline:
8
9
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder that is strongly associated with age. The aim of the present study was to describe current sex- and age-specific trends and regional differences in the incidence of IPD diagnosed in older people in Germany. This study was based on nationwide outpatient claims and drug prescription data from the German Statutory Health Insurance, covering approximately 87% of the general population. We conducted a cohort study in patients aged 50 years or older with observation time of at least 4 years. To assess the robustness of nationwide annual IPD incidence trends from 2013 to 2019, three case definitions with varying levels of stringency regarding coded outpatient diagnoses and drug prescriptions were applied. In 2019, the population at risk comprised 30,575,726 persons. Using the primary and most specific case definition, annual age- and sex-standardized cumulative IPD incidence decreased stepwise from 137 (2013) to 106 (2019) new cases per 100,000 persons. The decline in incidence was seen in both sexes, in all age groups and in the majority of German regions. The relative decrease (2013-2019) in the annual age- and sex-standardized IPD incidence varied from 23% to 28% among case definitions. Our findings indicate a nationwide decline in the age- and sex-standardized incidence of IPD from 2013 to 2019 in Germany. This trend was consistent using different case definitions. Further research is needed to elucidate the factors underlying this trend.
Sections du résumé
BACKGROUND AND PURPOSE
Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder that is strongly associated with age. The aim of the present study was to describe current sex- and age-specific trends and regional differences in the incidence of IPD diagnosed in older people in Germany.
METHODS
This study was based on nationwide outpatient claims and drug prescription data from the German Statutory Health Insurance, covering approximately 87% of the general population. We conducted a cohort study in patients aged 50 years or older with observation time of at least 4 years. To assess the robustness of nationwide annual IPD incidence trends from 2013 to 2019, three case definitions with varying levels of stringency regarding coded outpatient diagnoses and drug prescriptions were applied.
RESULTS
In 2019, the population at risk comprised 30,575,726 persons. Using the primary and most specific case definition, annual age- and sex-standardized cumulative IPD incidence decreased stepwise from 137 (2013) to 106 (2019) new cases per 100,000 persons. The decline in incidence was seen in both sexes, in all age groups and in the majority of German regions. The relative decrease (2013-2019) in the annual age- and sex-standardized IPD incidence varied from 23% to 28% among case definitions.
CONCLUSION
Our findings indicate a nationwide decline in the age- and sex-standardized incidence of IPD from 2013 to 2019 in Germany. This trend was consistent using different case definitions. Further research is needed to elucidate the factors underlying this trend.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3124-3131Informations de copyright
© 2023 European Academy of Neurology.
Références
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257-1272.
Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284-2303.
Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. J Neurol. 2010;257(7):1073-1082.
Dammertz LHJ, Ng F, Kohring C, Heuer J, Akmatov MK, Bätzing J. Morbus Parkinson in der vertragsärztlichen Versorgung-Regionale Unterschiede der Diagnoseprävalenz und Komorbiditätsanalysen anhand bundesweiter Abrechnungsdaten im Zeitraum 2010 bis 2019. Zentralinstitut für die kassenärztliche Versorgung in Deutschland (Zi). Versorgungsatlas-Bericht Nr. 22/01. Berlin 2022.
Deutsche Gesellschaft für Neurologie (DGN). DGN S3-Leitlinie Idiopathisches Parkinson-Syndrom-Langversion. 2016. Accessed August 15, 2022. https://www.awmf.org/uploads/tx_szleitlinien/030-010l_S3_Parkinson_Syndrome_Idiopathisch_2016-06-abgelaufen.pdf
Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology. 2000;55(9):1358-1363.
Heinzel S, Berg D, Binder S, et al. Do we need to rethink the epidemiology and healthcare utilization of Parkinson's disease in Germany? Front Neurol. 2018;9:500.
Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-953.
Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-386.
Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(suppl 1):S3-S8.
Lange R, Erbguth F. Parkinson's disease in the elderly. Z Gerontol Geriatr. 2017;50(6):547-559.
Nerius M, Fink A, Doblhammer G. Parkinson's disease in Germany: prevalence and incidence based on health claims data. Acta Neurol Scand. 2017;136(5):386-392.
Canonico M, Artaud F, Degaey I, et al. Incidence of Parkinson's disease in French women from the E3N cohort study over 27 years of follow-up. Eur J Epidemiol. 2022;37:513-523.
Brakedal B, Toker L, Haugarvoll K, Tzoulis C. A nationwide study of the incidence, prevalence and mortality of Parkinson's disease in the Norwegian population. NPJ Parkinsons Dis. 2022;8(1):19.
Okunoye O, Marston L, Walters K, Schrag A. Change in the incidence of Parkinson's disease in a large UK primary care database. NPJ Parkinsons Dis. 2022;8(1):23.
Bundesministerium für Gesundheit (BMG). Mitglieder und Versicherte der gesetzlichen Krankenversicherung (GKV)-Statistik über Versicherte gegliedert nach Status, Alter, Wohnort und Kassenart (Stichtag jeweils zum 1. Juli des Jahres). 2022. https://www.bundesgesundheitsministerium.de/themen/krankenversicherung/zahlen-und-fakten-zur-krankenversicherung/mitglieder-und-versicherte.html
Bohlken J, Riedel-Heller S, Kramer A, Kostev K, Schrag A. Trends in prevalence of Parkinson's disease in German general and neurological practices from 2010 to 2019. Fortschr Neurol Psychiatr. 2023;91(1-02):19-23.
Savica R, Grossardt BR, Bower JH, Ahlskog JE, Rocca WA. Time trends in the incidence of Parkinson disease. JAMA Neurol. 2016;73(8):981-989.
Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson's disease in 204 countries/territories from 1990 to 2019. Front Public Health. 2021;9:776847.
Watts N, Amann M, Arnell N, et al. The 2019 report of The Lancet Countdown on health and climate change: ensuring that the health of a child born today is not defined by a changing climate. Lancet. 2019;394(10211):1836-1878.
Darweesh SK, Koudstaal PJ, Stricker BH, Hofman A, Ikram MA. Trends in the incidence of Parkinson disease in the general population: the rotterdam study. Am J Epidemiol. 2016;183(11):1018-1026.
Akushevich I, Kravchenko J, Ukraintseva S, Arbeev K, Yashin AI. Time trends of incidence of age-associated diseases in the US elderly population: medicare-based analysis. Age Ageing. 2013;42(4):494-500.
Lix LM, Hobson DE, Azimaee M, Leslie WD, Burchill C, Hobson S. Socioeconomic variations in the prevalence and incidence of Parkinson's disease: a population-based analysis. J Epidemiol Community Health. 2010;64(4):335-340.
Lee SH, Lee SJ, Kim YJ. Region-based analysis of prevalence and incidence of Parkinson's disease: analysis of the national sample cohort in South Korea. J Clin Neurol. 2018;14(4):478-486.
Liu CC, Li CY, Lee PC, Sun Y. Variations in incidence and prevalence of Parkinson's disease in Taiwan: a population-based Nationwide study. Parkinsons Dis. 2016;2016:8756359.
Wong JJ, Kwong JC, Tu K, et al. Time trends of the incidence, prevalence, and mortality of Parkinsonism. Can J Neurol Sci. 2019;46(2):184-191.
Hugh-Jones ME, Peele RH, Wilson VL. Parkinson's disease in Louisiana, 1999-2012: based on hospital primary discharge diagnoses, incidence, and risk in relation to local agricultural crops, pesticides, and aquifer recharge. Int J Environ Res Public Health. 2020;17(5):1584.
Hugh-Jones ME. [MA V, MPH, PhD, FeACE, HonFRCVS], Louisiana State University (LSU), Department of Environmental Sciences, Baton Rouge, LA, USA. (Personal Communication, 06 June 2022).
Breckenridge CB, Berry C, Chang ET, Sielken RL Jr, Mandel JS. Association between Parkinson's disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis. PLoS One. 2016;11(4):e0151841.
Isotalo J, Vahlberg T, Kaasinen V. Unchanged long-term rural-to-urban incidence ratio of Parkinson's disease. Mov Disord. 2017;32(3):474-475.
Chubak J, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic health care data algorithms. J Clin Epidemiol. 2012;65(3):343-349.e342.
Harding Z, Wilkinson T, Stevenson A, et al. Identifying Parkinson's disease and parkinsonism cases using routinely collected healthcare data: a systematic review. PLoS One. 2019;14(1):e0198736.
Abbas S, Ihle P, Köster I, Schubert I. Estimation of disease incidence in claims data dependent on the length of follow-up: a methodological approach. Health Serv Res. 2012;47(2):746-755.